SCYNEXIS to Participate in Upcoming Scientific Conferences and Events

JERSEY CITY, N.J., March 02, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc.,  (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced its participation in three in-person medical conferences and one virtual investor panel in March. Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will participate in a live panel discussion on drug development in Women’s Health. Event details can be found below:


  • International Society for the Study of Women’s Sexual Health (ISSWSH)
    Date: March 3-6, 2022
    Location: Dallas        
    Event Page
  • Council on Resident Education in Obstetrics and Gynecology (CREOG) & Association of Professors of Gynecology and Obstetrics (APGO) Annual Meeting
    Date: March 9-12, 2022
    Location: Orlando
    Event Page
  • Academy of Managed Care Pharmacy (AMCP)
    Date: March 29- April 1, 2022
    Location: Chicago
    Event Page

Virtual Investor Panel:

  • Maxim Group’s Annual Growth Conference
    Panel: Women’s Health Virtual Event
    Date: March 28, 2022
    Location: Virtual
    Time: 3:00 p.m. ET
    Event Page


SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS scientists are developing the company’s lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. SCYNEXIS has initiated the launch of its first commercial product in the U.S., BREXAFEMME® (ibrexafungerp tablets). The U.S. Food and Drug Administration (FDA) approved BREXAFEMME on June 1, 2021. In addition, late-stage clinical investigation of oral ibrexafungerp for the prevention of recurrent vulvovaginal candidiasis (VVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. For more information, visit

Investor Relations
Irina Koffler
Managing Director
LifeSci Advisors, LLC

Media Relations
Gloria Gasaatura
LifeSci Communications

Primary Logo

Back to news